Shares of Biocon hit an over six-month high of Rs 410.50, up 3 per cent on the BSE in Tuesday’s intra-day trade after its subsidiary Biocon Pharma received approval of its ANDA for Posaconazole Delayed-Release tablets from the US Food & Drug Administration (USFDA).
Biocon in an exchange filing said, this product is indicated for use in the prevention of certain fungal infections in patients with severely weakened immune systems and is available in 100mg strength. This approval further adds to Biocon’s portfolio of vertically integrated complex drug product, the company said.
The stock of biotechnology company traded at its highest level since July 20, 2021. In the past three weeks, the stock has outperformed the market by surging 18 per cent, as compared to a nearly 6 per cent decline in the S&P BSE Sensex.
At 10:52 am; the stock was up 2 per cent, as against a 0.7 per cent decline in the benchmark index. The counter saw huge trading volume with a combined around 5 million equity shares changing hands on the NSE and BSE.
In October-December quarter (Q3FY22), Biocon’s consolidated revenues grew by 18 per cent year-on-year (YoY) to Rs 2,223 crore, driven by a strong performance across all business segments. Net profit jumped 11 per cent at Rs 187 crore on YoY basis.
Earnings before interest tax and depreciation and amortization (Ebitda) grew by 25 per cent YoY at Rs 537 crore, which was impacted by mark- to- market loss attributed to Biocon Biologics’ equity investment in Adagio. Ebitda margin improved to 24 per cent from 23 per cent in a year ago quarter.
While announcing Q3 results on January 20, 2022, the company’s management said Biocon Biologics achieved a key milestone with the commercialization of the world's first interchangeable biosimilar, Insulin Glargine, in the U.S. Approvals for several of generics and biosimilars in global markets, and renewal of key long-term research service agreements at Syngene, position the company for a strong close to this fiscal, it added.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU